A Short Note on Netarsudil
S. Padmaja
Department of Pharmacology, Chettinad Hospital and Research Institute, Chettinad Academy of Research and Education, Kelambakkam-603103, Tamil Nadu, India.
R. Srivignesh *
Department of Pharmacology, Chettinad Hospital and Research Institute, Chettinad Academy of Research and Education, Kelambakkam-603103, Tamil Nadu, India.
*Author to whom correspondence should be addressed.
Abstract
Glaucoma currently affects over 60 million people worldwide and also one of the leading cause of irreversible blindness. Early Medical intervention is the preliminary therapy to prevent the progression of optic nerve damage and vision loss by reducing the Intra Ocular Pressure (IOP). IOP is the regulated balance between production of aqueous humour and the rate of aqueous flow via uveoscleral outflow pathway and trabecular meshwork pathway (TM). There are many groups of drugs like beta blockers, carbonic anhydrous inhibitors, prostaglandin analogues etc., are available. Netasurdil which is the Rho – associated protein kinase (ROCK) inhibitor is the novel group of drugs which has been in research for the Glaucoma.
Keywords: Netarsudil, glacuoma, intraocular pressure